ArticleAngewandte Chemie (International ed. in English)2026
Proteome-Wide Target Identification Using Reactive Metallo-Scaffolds (r-mS): A Platform for Metallodrug Discovery.
Article in Angewandte Chemie (International ed. in English), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Metal complexes offer unique opportunities as scaffolds in chemical biology and drug discovery, with tunable geometries, modular coordination environments, and structural features not readily accessible with organic molecules. Here, we introduce reactive metallo-scaffolds (r-mS) as a class of metal complexes designed to map ligandable cysteines across the mammalian proteome. These covalent warhead-bearing metal complexes use the metal centre and ligand architecture to modulate cysteine engagement, with cysteine labelling occurring through the electrophilic chloroacetamide warhead. Using chemoproteomics, we profiled a focused r-mS series in HEK293T lysate, identifying novel cysteine ligandability and demonstrating how metal identity, arene substituents and overall molecular topography govern cysteine reactivity and proteome-wide targeting. Among the series screened, r-mS-2 emerged as the most productive scaffold, which engaged cysteine 119 within the functionally relevant SAM-binding domain of PRMT1. This interaction was validated by intact protein LC-MS and was determined to functionally inhibit the activity of PRMT1. Structural modelling and docking provided insights into the molecular basis of binding, which implied π-stacking and electrostatic complementarity in driving covalent engagement. Together, these results position reactive metallo-scaffolds (r-mS) as a versatile platform for proteome-wide covalent ligand discovery and the rational development of next-generation metallodrugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.